Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations

HIV Medicine

Volumn 10, Issue 4, 2009, Pages 229-235

  Audsley, J ^a,b,c   Arrifin, N ^b   Yuen, L K W ^d   Ayres, A ^d   Crowe, S M ^a,b,e   Bartholomeusz, A ^d   Locarnini, S A ^d   Mijch, A ^a,b   Lewin, S R ^a,b,c   Sasadeusz, Joe ^b,c,d  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^e BURNET INSTITUTE   (Australia)

Author keywords

HBV polymerase mutations; HIV HBV coinfection; Tenofovir

Indexed keywords

DNA POLYMERASE; LAMIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; P PROTEIN, HEPATITIS B VIRUS; PHOSPHONIC ACID DERIVATIVE; POL PROTEIN; TENOFOVIR;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIXED INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; TREATMENT DURATION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; CROSS-SECTIONAL STUDY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MIDDLE AGED; MUTATION; VIREMIA; VIROLOGY;

ADENINE; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENE PRODUCTS, POL; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; ORGANOPHOSPHONATES; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; VIRAL LOAD; VIREMIA;

EID: 62749093745     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00675.x     Document Type: Article

References (41)

1. UNAIDS. Report on the global AIDS epidemic 2008.
2. WHO. WHO fact sheet No 4, hepatitis B. World Health Organization. 2008, pp. 1-2
3. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188: 571-577.
4. Konopnicki D, Mocroft A, de Wit S et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA Cohort. AIDS 2005; 19: 593-601.
5. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol 1997; 27: 18-24.
6. Thomas DL, Cannon RO, Shapiro CN, Hook EW III, Alter MJ, Quinn TC. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis 1994; 169: 990-995.
7. Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003; 4: 241-249.
8. Colin J, Cazals-Hatem D, Loriot M et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29: 1306-1310.
9. Gilson RJ, Hawkins AE, Beecham MR et al. Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection. AIDS 1997; 11: 597-606.
10. Thio CL, Seaberg EC, Skolasky R Jr et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926.
11. Benhamou Y, Bochet M, Thibault V et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302-1306.
12. Matthews GV, Bartholomeusz A, Locarnini S et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20: 863-870.
13. Allen MI, Deslauriers M, Webster Andrews C et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27: 1670-1677.
14. Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006; 78: S52-S55.
15. Bartholomeusz A, Tehan BG, Chalmers DK. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 2004; 9: 149-160.
16. Delaney WE, Yang H, Westland CE et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77: 11833-11841.
17. Benhamou Y, Fleury H, Trimoulet P et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006; 43: 548-555.
18. Sheldon J, Camino N, Rodes B et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10: 727-734.
19. Gan RB, Chu MJ, Shen LP, Qian SW, Li ZP. The complete nucleotide sequence of the cloned DNA of hepatitis B virus subtype adr in pADR-1. Sci Sin [B] 1987; 30: 507-521.
20. Ayres A, Locarnini S, Bartholomeusz A. HBV genotyping and analysis for unique mutations. Methods Mol Med 2004; 95: 125-149.
21. Bartholomeusz A, Locarnini S, Ayres A et al. Molecular modelling of hepatitis B virus polymerase and adefovir resistance identifies three clusters of mutations. Hepatology 2004; 40: 246A.
22. Yuen LKW, Ayres A, Littlejohn M et al. SEQHEPB: A sequence analysis program and relational database system for chronic hepatitis B. Antivir Res 2007; 75: 64-74.
23. Dore GJ, Cooper DA, Pozniak AL et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naïve and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 1185-1192.
24. Ristig MB, Crippin J, Aberg JA et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/ hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002; 186: 1844-1847.
25. Stephan C, Berger A, Carlebach A et al. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother 2005; 56: 1087-1093.
26. Schooley RT, Ruane P, Myers RA et al. Tenofovir DF in antiretroviral-experienced patients: Results from a 48-week, randomized, double-blind study. AIDS 2002; 16: 1257-1263.
27. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9: 353-363.
28. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10: 625-633.
29. Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16: 2352-2354.
30. Schmutz G, Nelson M, Lutz T et al. Combination of tenofovir and lamivudine vs. tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006; 20: 1951-1954.
31. Nelson M, Portsmouth S, Stebbing J et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003; 17: F7-F10.
32. Bani-Sadr F, Palmer P, Scieux C, Molina JM. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. Clin Infect Dis 2004; 39: 1062-1064.
33. Lacombe K, Gozlan J, Boelle PY et al. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS 2005; 19: 907-915.
34. Sheldon J, Camin N, Rodes B et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10: 727-734.
35. Peters MG, Andersen J, Lynch P et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006; 44: 1110-1116.
36. Jain MK, Comanor L, White C et al. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: Factors associated with response. J Viral Hepat 2007; 14: 176-182.
37. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48: 391-398.
38. van Bömmel F, Zöllner B, Sarrazin C et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318-325.
39. Marcellin P, Buti M, Krastev Z et al. A randomized, double-blind, comparison of tenofovir DF (TDF) vs. adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): Study Gs-US-174-0101. Am Assoc Study Liv Dis 2007; Vol 46 (Suppl. 1): 290A-291A.
40. Heathcote EJ, Gane E, DeMan R et al. A randomized, double-blind, comparison of tenofovir DF (TDF) vs. adefovir dipivoxil (ADV) for the treatment of HBeAg-positive chronic hepatitis B (CHB): Study GS-US-174-0103. Am Assoc Study Liv Dis 2007; Vol 46 (Suppl. 1): 861A.
41. van der Eijk AA, Hansen BE, Niesters HG et al. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepat 2005; 12: 364-372.